- Home
- ELDN
as 07-26-2024 4:00pm EST
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 104.0M | IPO Year: | N/A |
| Target Price: | $11.67 | AVG Volume (30 days): | 117.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $3.35 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Eledon Pharmaceuticals Inc. News
ELDN Breaking Stock News: Dive into ELDN Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewswire
2 months ago
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GlobeNewswire
3 months ago
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
GlobeNewswire
3 months ago
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
GlobeNewswire
3 months ago
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
GlobeNewswire
3 months ago
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
GlobeNewswire
4 months ago
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
GlobeNewswire
4 months ago
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Compare ELDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELDN Eledon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.